Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
NEUROLOGY / BASIC RESEARCH
Inhibition of glioma cell viability by jatrophone via NF-κB down-regulation and apoptosis inhibitor up-regulation
1
Postgraduate Training Base of Rocket Army Special Medical Center of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, Liaoning, China
2
Department of Neurosurgery, Rocket Army Medical Center, Beijing, China
Submission date: 2020-01-02
Final revision date: 2020-02-20
Acceptance date: 2020-02-23
Online publication date: 2020-04-15
Publication date: 2025-02-28
Corresponding author
Arch Med Sci 2025;21(1):224-232
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The present study evaluated the pro-survival signaling pathway inhibition potential of jatrophone in glioblastoma cells with the intention to develop effective treatment for glioblastoma.
Material and methods:
Changes in proliferation of cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological changes were evaluated by electron microscopy and apoptosis by flow cytometry.
Results:
The proliferative potential of glioma cells showed significant reduction on treatment with jatrophone. The shrinkage and detachment from the flask surface was prominent in glioma cells on treatment with 15 µM jatrophone. Treatment with jatrophone (4.8 µM) for 72 h increased apoptosis in U87MG and A172 cells. The immunocytochemistry showed a significant decrease in the level of intracellular NF-κB p65 in glioma cells on treatment with jatrophone. Jatrophone treatment significantly suppressed nuclear NF-κB p65/total NF-κB p65 in glioma cells. Treatment with jatrophone suppressed levels of survivin, XIAP and Bcl-2 in glioma cells relative to control. The Bax level in glioma cells was enhanced markedly relative to control on treatment with jatrophone. Activation of caspase-9 and -3 in glioma cells was markedly increased on treatment with jatrophone.
Conclusions:
Jatrophone acts as inhibitory agent for glioblastoma cell proliferation and mediator of apoptosis. Therefore, jatrophone can be used as a therapeutic agent for glioblastoma treatment.
The present study evaluated the pro-survival signaling pathway inhibition potential of jatrophone in glioblastoma cells with the intention to develop effective treatment for glioblastoma.
Material and methods:
Changes in proliferation of cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological changes were evaluated by electron microscopy and apoptosis by flow cytometry.
Results:
The proliferative potential of glioma cells showed significant reduction on treatment with jatrophone. The shrinkage and detachment from the flask surface was prominent in glioma cells on treatment with 15 µM jatrophone. Treatment with jatrophone (4.8 µM) for 72 h increased apoptosis in U87MG and A172 cells. The immunocytochemistry showed a significant decrease in the level of intracellular NF-κB p65 in glioma cells on treatment with jatrophone. Jatrophone treatment significantly suppressed nuclear NF-κB p65/total NF-κB p65 in glioma cells. Treatment with jatrophone suppressed levels of survivin, XIAP and Bcl-2 in glioma cells relative to control. The Bax level in glioma cells was enhanced markedly relative to control on treatment with jatrophone. Activation of caspase-9 and -3 in glioma cells was markedly increased on treatment with jatrophone.
Conclusions:
Jatrophone acts as inhibitory agent for glioblastoma cell proliferation and mediator of apoptosis. Therefore, jatrophone can be used as a therapeutic agent for glioblastoma treatment.
REFERENCES (33)
1.
Preusser M, de Ribaupierre S, Wöhrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011; 70: 9-21.
2.
Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756-84.
3.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
5.
Darefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 2012; 118: 2163-72.
6.
Hegi ME, Janzer RC, Lambiv WL, et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 2012; 123: 841-52.
7.
Kisková T, Ekmekcioglu C, Garajová M, et al. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Eur J Cancer Prev 2012; 21: 163-70.
8.
Lee MH, Choi BY, Kundu JK, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res 2009; 69: 7449-58.
9.
Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 2011; 6: e20849.
10.
Xiong J, Cheng G, Tang H, Zhen HN, Zhang X. Ardipusilloside I induces apoptosis in human glioblastoma cells through a caspase-8independent FasL/Fas-signaling pathway. Environ Toxicol Pharmacol 2009; 27: 264-70.
11.
Lin H, Zhang X, Cheng G, et al. Apoptosis induced by ardipusilloside III through BAD dephosphorylation and cleavage in human glioblastoma U251MG cells. Apoptosis 2008; 13: 247-57.
12.
Jiang H, Shang X, Wu H, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 2009; 8: 25-33.
13.
Devappa RK, Makkar HP, Becker K. Nutritional, biochemical, and pharmaceutical potential of proteins and peptides from jatropha: review. J Agric Food Chem 2010; 58: 6543-55.
14.
Lillo MA, Nichols C, Perry C, et al. Methylparaben stimulates tumor initiating cells in ER+ breast cancer models. J Appl Toxicol 2017; 37: 417-25.
15.
Vidal G, Bursac Z, Miranda-Carboni G, White-Means S, Starlard-Davenport A. Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee. Cancer Med 2017; 6: 1776-86.
16.
Meryem KE, Gulcin SE, Ecmel IK, et al. Etanercept protects ovarian reserve against ischemia/reperfusion injury in a rat model. Arch Med Sci 2019; 15: 1104-12.
17.
Haixia G, Yuelin H, Chaoke B, Zhiyong P. Antitumor and apoptotic effects of 5-methoxypsoralen in U87MG human glioma cells and its effect on cell cycle, autophagy and PI3K/Akt signaling pathway. Arch Med Sci 2019; 15: 1530-8.
18.
Zichuan W, Nan C, Jin Y, Qingzhong W, Aimin L. Microarray gene profiling analysis of glioblastoma cell line U87 reveals suppression of the FANCD2/Fanconi anemia pathway by the combination of Y15 and temozolomide. Arch Med Sci 2019; 15: 1035-46.
19.
Long Y, Lu J, Dongdong J, Baiying L, Shi J. The protective effects of salvianolic acid A against hepatic ischemia-reperfusion injury via inhibiting expression of toll-like receptor 4 in rats. Arch Med Sci 2019; 15: 1599-607.
20.
Motomura K, Natsume A, Kishida Y, et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 2011; 117: 1721-30.
21.
Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFkappaB pathway: a therapeutic target in glioblastoma. Oncotarget 2011; 2: 646-53.
22.
Smith D, Shimamura T, Barbera S, Bejcek BE. NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem 2008; 307: 141-7.
23.
Zhao X, Laver T, Hong SW, et al. An NFkappaB p65-cIAP2 link is necessary for mediating resistance to TNFalpha induced cell death in gliomas. J Neurooncol 2011; 102: 367-81.
24.
Guo K, Kang NX, Li Y, et al. Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC Cancer 2009; 9: 100.
25.
Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010; 21: 864-70.
26.
Pavlyukov MS, Antipova NV, Balashova MV, et al. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem 2011; 286: 23296-307.
27.
Zanotto-Filho A, Braganhol E, Schröder R, et al. NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2011; 81: 412-24.
28.
George J, Banik NL, Ray SK. Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo. Neuro Oncol 2010; 12: 1088-101.
29.
Kogiku M, Ohsawa I, Matsumoto K, et al. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci 2008; 15: 1198-203.
30.
Angileri FF, Aguennouz M, Conti A, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 2008; 112: 2258-66.
31.
Zhen HN, Zhang X, Hu PZ, et al. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 2005; 105: 2775-83.
32.
Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5.
33.
Chen XQ, Yang S, Li ZY, et al. Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol Med Report 2012; 5: 917-22.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
